Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up – Still a Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price gapped up prior to trading on Monday . The stock had previously closed at $38.89, but opened at $43.53. Definium Therapeutics shares last traded at $41.30, with a volume of 1,762,185 shares traded.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its second Phase 3 study of DT120 ODT met its primary endpoint, showing a statistically significant improvement in anxiety symptoms among patients with GAD. The successful result follows positive findings from an earlier late-stage study, providing additional support for the drug’s potential efficacy. Definium’s LSD-based drug lowers anxiety in second successful late-stage study
• Positive Sentiment: The company’s Panorama Phase 3 trial achieved its goal, with topline data indicating meaningful anxiety improvement. Investors are likely viewing the readout as an important step toward a potential regulatory submission for DT120 ODT. Definium Therapeutics Announces Positive Topline Results
• Positive Sentiment: Needham reaffirmed its Buy rating and set a $66 price target, while Royal Bank of Canada previously assigned an Outperform rating. The bullish analyst views add support to the positive market reaction. Definium Therapeutics Earns Outperform Rating
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, reflecting heightened volatility around the Phase 3 disclosure. The company also scheduled a webcast to discuss the results. Definium to Discuss Topline Results
• Neutral Sentiment: Definium granted options covering 56,650 shares to three new employees. The grants may create limited future dilution but are primarily intended as hiring incentives. Definium Announces New Employee Inducement Grants

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on DFTX shares. Bank of America began coverage on Definium Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $75.00 target price for the company. Royal Bank Of Canada reissued an “outperform” rating and set a $66.00 price target on shares of Definium Therapeutics in a research note on Friday. Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of Definium Therapeutics in a report on Monday. Wells Fargo & Company upped their price objective on Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Finally, Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $63.00.

Definium Therapeutics Trading Up 3.5%

The firm has a market capitalization of $5.41 billion, a P/E ratio of -11.73 and a beta of 2.23. The stock has a 50-day simple moving average of $43.01 and a two-hundred day simple moving average of $30.33. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, equities research analysts anticipate that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Insider Buying and Selling at Definium Therapeutics

In other news, insider Mark Sullivan sold 13,008 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. The trade was a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 67,119 shares of company stock valued at $2,887,496 in the last 90 days. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

A number of large investors have recently bought and sold shares of DFTX. Russell Investments Group Ltd. lifted its holdings in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. Nykredit A S purchased a new position in shares of Definium Therapeutics in the 2nd quarter valued at $45,000. BNP Paribas Financial Markets raised its position in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares in the last quarter. Allworth Financial LP bought a new position in shares of Definium Therapeutics in the 2nd quarter worth $110,000. Finally, Caxton Associates LLP purchased a new stake in shares of Definium Therapeutics during the 3rd quarter worth $126,000. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.